James P. Agalloco - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
James P. Agalloco


James P. Agalloco Pharmtech editorial advisory board (EAB) member

James P. Agalloco
President,
Agalloco & Associates

Agalloco is a past president of the Parenteral Drug Association (PDA) and served as an officer or director of PDA from 1982 to 1993. He has authored or co-authored more than 90 papers and lectured extensively on sterilization, aseptic processing, and validation at various PDA, PMA, the International Society for Pharmaceutical Engineering (ISPE), and Pharmaceutical Technology meetings, domestically as well as internationally. He is a member of USP’s Microbiology and Sterility Assurance Expert Committee for 2005–2010. Agalloco is a member of the editorial advisory boards of Pharmaceutical Technology and Pharmaceutical Manufacturing, and serves on the scientific advisory boards of Laureate, MEDInstill, MODA, and IPS.

He is a frequent author and lecturer on the subject of sterilization, aseptic processing, and process validation.

James Agalloco is president of Agalloco & Associates, which provides a range of technical services to the pharmaceutical and biotechnology industry. Since the formation of the company in 1991, Agalloco has assisted more than 100 healthcare firms in a wide range of validation, automation and compliance areas. During his more than 35 years of industry experience, he has worked in organic synthesis, pharmaceutical formulation, pharmaceutical production, project and process engineering, validation and process automation during his career at Merck, Pfizer, Squibb and Bristol-Myers Squibb.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
14%
Less restrictive inventory control by pharmaceutical companies
9%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here